Everest Medicines Acquires VIZZ® Eyedrops in $125 Million China Deal
1h ago|4 min read2Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Seeking Alpha reported on June 8, 2026, that Everest Medicines has secured exclusive rights to develop and commercialize LENZ Therapeutics' presbyopia eyedrop VIZZ® in Greater China. The deal includes an upfront payment and milestones totaling $125 million. Everest gains access to an asset with a U.S. FDA approval decision pending on or before March 31, 2027, aiming to tap a market where over half the adult population aged 40 and above experiences presbyopia.
This acquisition represents a strategic shift for Everest Medicines towards late-stage, near-commercial assets. Historically, the company has focused on earlier-stage clinical development in areas like infectious diseases, with its 2021 acquisition of nephrology drug Nefecon being a notable prior investment. The move into ophthalmology with VIZZ® is a new therapeutic area for the company.
The backdrop is a global aging demographic and rising demand for convenient vision correction solutions in China. The country's over-60 population is projected to exceed 400 million by 2035. Non-invasive pharmaceutical options are gaining traction as alternatives to reading glasses or surgical procedures.
The trigger for the deal now is the imminent U.S. regulatory catalyst for VIZZ®. The FDA accepted LENZ's New Drug Application in late 2025 and assigned a target action date in Q1 2027. Securing rights ahead of a potential U.S. approval allows Everest to initiate local regulatory and commercial planning immediately, positioning itself as an early mover.
The financial terms of the agreement include a $15 million upfront payment to LENZ Therapeutics. Everest will pay up to an additional $110 million in development, regulatory, and sales-based milestones. Everest will fund all development and commercialization costs in Greater China and pay tiered royalties on net sales.
The potential market size is substantial. Presbyopia affects an estimated 210 million people in China. VIZZ®, a once-daily pilocarpine hydrochloride ophthalmic solution, is designed to improve near vision without impacting distance vision. This differentiates it from the primary market incumbent, VUITY® (pilocarpine HCl ophthalmic solution 1.25%), which reported U.S. net sales of $214 million in 2025.
| Metric | LENZ (Global) | Everest (Greater China Rights) |
|---|---|---|
| Upfront Payment | Receives $15M | Pays $15M |
| Total Deal Value | Up to $125M | Up to $125M |
| Key Catalyst | FDA PDUFA date by Mar 31, 2027 | Initiate local development & regulatory filing |
Peers in the space trade at significant premiums. LENZ Therapeutics itself holds a market capitalization of approximately $850 million. This deal values the Greater China rights at a fraction of LENZ's total value but provides non-dilutive capital to LENZ while offering Everest a defined commercial pathway.
The transaction has clear second-order effects. For LENZ Therapeutics (LENZ), the deal provides immediate cash to bolster its balance sheet ahead of its U.S. commercial launch and validates its asset's global potential. It reduces perceived geographic risk for LENZ investors. For Everest Medicines (HKEX: 1952.HK), it diversifies the revenue pipeline beyond its lead assets, potentially reducing stock volatility tied to single-project outcomes.
Competitive pressure will likely increase on other ophthalmology-focused firms in China, such as Zhaoke Ophthalmology (HKEX: 6622.HK), which markets a portfolio of eye care products. The introduction of a novel pharmaceutical option could shift market share from traditional optical retailers. Suppliers of pilocarpine API and ophthalmic drug delivery systems may see incremental demand.
A key limitation is the binary risk of the U.S. FDA decision. A complete response letter or delay for VIZZ® would negatively impact the asset's perceived value and Everest's development timeline in China. local regulatory approval in China is not guaranteed and typically lags behind the U.S. by several years.
Positioning data suggests institutional flows have been mixed in Chinese healthcare. Recent weeks saw net outflows from broad biotech ETFs, but specific M&A activity like this can drive isolated long interest. Traders may initiate pairs trades, going long Everest versus peers lacking near-term catalysts.
The primary catalyst is the U.S. FDA's Prescription Drug User Fee Act (PDUFA) action date for VIZZ®, set for on or before March 31, 2027. Investors will monitor for any FDA advisory committee meeting announcement, typically scheduled 2-3 months prior to the PDUFA date.
For Everest Medicines, the next milestones are the anticipated submission of a clinical trial application to Chinese regulators in the second half of 2026 and the initiation of a bridging study in China. The company's quarterly cash burn rate, reported at roughly $25 million per quarter, will be scrutinized to assess funding needs post-deal.
Levels to watch include LENZ's stock price reaction around the $15 million cash receipt confirmation. Support for Everest's share price rests on maintaining its cash runway above 12 months. Should the U.S. FDA approve VIZZ® on schedule, expect upward re-rating for both stocks and increased licensing interest in other geographic regions.
Presbyopia is the age-related loss of near vision, typically starting after age 40. It is caused by a hardening of the eye's lens, reducing its ability to focus on close objects. In China, the condition affects over 210 million adults, creating a substantial addressable market for pharmaceutical treatments like VIZZ®. The sheer scale of the aging population makes China a strategically critical market for any ophthalmology company.
Both VIZZ® and VUITY® (marketed by AbbVie) are once-daily pilocarpine hydrochloride eyedrops. The key claimed differentiation for VIZZ® is its proprietary formulation, designed to optimize duration of effect and minimize side effects like headache or dimming of distance vision. Direct head-to-head clinical data is limited, so commercial success will hinge on real-world efficacy, tolerability, and pricing strategies in each market.
The deal commits Everest to up to $125 million in potential payments, starting with a $15 million upfront cash outlay. This expenditure will increase near-term cash burn but adds a late-stage asset with a defined U.S. regulatory catalyst. Investors will monitor whether this acquisition accelerates Everest's path to profitability or necessitates further capital raising through equity or debt markets within the next 18 months.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.